Incyte Corporation

This phase 3 trial tests an oral drug called povorcitinib in 346 adults with prurigo nodularis, a condition causing intense itching and bumpy skin lesions. The study compares the drug to a placebo over 24 weeks to see if it reduces itch and clears the skin. If successful, it coul…

This study gives continued access to the drug itacitinib for 18 people who were already taking it in earlier trials for myelofibrosis, bronchiolitis obliterans after lung transplant, or chronic graft-versus-host disease. Participants keep taking the same dose as before, as long a…

This study tests a modified dosing schedule of the drug tafasitamab given together with lenalidomide in people whose diffuse large B-cell lymphoma has come back or stopped responding to treatment. The trial includes 53 adults who have had at least one prior therapy but are not el…

This study tests a new drug called INCB099280 in 73 people with advanced solid tumors who have not received immunotherapy before. The goal is to see if the drug can shrink tumors and to check for side effects. The study focuses on safety and how well the drug works in the short t…

This Phase 2 trial tests whether adding axatilimab to the standard drug ruxolitinib works better for people newly diagnosed with moderate to severe chronic graft-versus-host disease (cGVHD), a complication after stem cell transplant. About 130 participants aged 12 and older will …

This study tests whether adding the drug tafasitamab to a standard two-drug combination (lenalidomide plus rituximab) can help people with relapsed or refractory follicular lymphoma or marginal zone lymphoma live longer without their cancer getting worse. About 654 adults who hav…

This study tests a new drug called axatilimab against the best current treatments for people with chronic graft-versus-host disease (cGVHD), a complication after a stem cell transplant. Participants must be at least 12 years old and have tried at least two prior treatments withou…

This study tests a new drug called INCB099280 in 63 adults with advanced squamous cell skin cancer that cannot be removed by surgery or radiation. The main goals are to see if the drug shrinks tumors and to check its safety. Participants take the drug and are monitored for side e…

This study offers ongoing treatment with ruxolitinib (alone or with other cancer therapy) to people with pancreatic, colorectal, breast, or lung cancer who were already benefiting from it in a previous study. It includes only 10 participants who had stable disease and were tolera…

This study tests a combination of two drugs, tafasitamab and lenalidomide, in adults with diffuse large B-cell lymphoma that has come back or not responded to prior treatments. Participants have had 1 to 3 previous therapies but cannot receive high-dose chemo or a stem cell trans…

This study tests whether adding two drugs, tafasitamab and lenalidomide, to standard chemotherapy (R-CHOP) helps people with a fast-growing type of lymphoma called DLBCL. About 900 patients with high-risk disease will take part. The goal is to see if the new combination keeps can…

This phase 3 study tests whether adding the drug INCMGA00012 to standard chemotherapy helps people with advanced non-small cell lung cancer live longer. About 583 participants with either squamous or nonsquamous lung cancer who have not had prior treatment will be enrolled. The s…

This early-stage study tests a new drug called INCB057643, given alone or with another drug (ruxolitinib), for people with myelofibrosis and other advanced blood cancers. The main goal is to check safety and side effects. About 140 adults whose cancer has not responded to prior t…

This early-stage study tests an experimental drug called INCB186748 in people with advanced or spreading solid tumors that have a specific genetic change called KRAS G12D. The main goals are to check the drug's safety and find the right dose. About 30 adults whose cancer has not …

This study tests a new drug called povorcitinib for people with nonsegmental vitiligo, a condition that causes white patches on the skin. About 467 adults will take either the drug or a placebo daily for 52 weeks to see if it safely helps bring back skin color. Participants must …

This study tests a daily pill called povorcitinib to see if it can safely bring back skin color in people with nonsegmental vitiligo, a condition where white patches appear on the skin. About 450 adults will receive either the drug or a placebo for 52 weeks. The main goal is to m…

This study offers continued treatment with the drug parsaclisib (alone or with other drugs) to people with B-cell cancers who were already taking it in an earlier study and were benefiting. The main goal is to check safety and side effects. About 112 participants will take part.

This study tests a prescription cream called ruxolitinib for children and teens (ages 6 to 17) with moderate eczema. The cream is applied to the skin to reduce redness, itching, and rash. Researchers want to see if it works better than a cream with no medicine and check for side …

This study tests an experimental drug called povorcitinib for people with prurigo nodularis, a skin condition causing intense itching and hard bumps. About 349 adults aged 18 to 75 with at least 20 itchy lesions will receive either the drug or a placebo. The main goal is to see i…

This early-stage study is testing a new drug, INCA033989, in 72 healthy adults aged 18 to 55. The goal is to see how the drug moves through the body and whether it is safe when given as a shot under the skin or through an IV. No disease is being treated — this is a first step to …